Ots M, Mackenzie H S, Troy J L, Rennke H G, Brenner B M
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
J Am Soc Nephrol. 1998 Feb;9(2):224-30. doi: 10.1681/ASN.V92224.
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rate of progression of experimental renal disease. Although the end result of both classes of drugs is to block the renin-angiotensin system (RAS), ACEI and AT1RA act at different sites in the RAS cascade. The aim of this study was to compare the effects of an ACEI (enalapril) and AT1RA (losartan), alone or in combination, in slowing the progression of experimental renal disease in a model of reduced renal mass. Two weeks after 5/6 renal ablation, rats were divided into five groups matched for body weight, systolic BP (SBP), and urinary protein excretion rate (UprotV). The effects on SBP and UprotV of treatment with 25 and 40 mg/L enalapril (groups I and II; both n = 7), 180 mg/L losartan (group III, n = 8), or a combination of enalapril (25 mg/L) + losartan (180 mg/L) (group IV, n = 9) versus vehicle (group V, n = 9) were studied for 12 wk. Remnant kidneys were then assessed histologically for evidence of focal and segmental glomerulosclerosis and hyalinosis (FSGS), and interstitial fibrosis. There were no significant differences (NSD) in body weight among the groups at any time. Combination therapy reduced SBP (122 +/- 8 mmHg) significantly at 12 wk to levels similar to losartan (127 +/- 3 mmHg) or enalapril (40 mg/L) alone (124 +/- 5 mmHg) (P < 0.05 versus vehicle controls). With equivalent antihypertensive effects, no differences in frequency of FSGS were discerned among the treatment groups (groups II through IV; F = 1.7, NSD). Tubulointerstitial injury scores followed a similar pattern. BP was highly correlated with the extent of FSGS, both among individual rats (r = 0.68, P = 0.05) and the group means (r = 0.99, P = 0.001). We conclude that the renoprotective effects of enalapril, losartan, or combination therapy are similar in this model over the 12 wk of the study, and are closely related to the magnitude of their antihypertensive effects.
血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体拮抗剂(AT1RA)可减缓实验性肾病的进展速度。尽管这两类药物的最终作用都是阻断肾素-血管紧张素系统(RAS),但ACEI和AT1RA作用于RAS级联反应的不同位点。本研究的目的是比较ACEI(依那普利)和AT1RA(氯沙坦)单独或联合使用在减轻肾质量减少模型中实验性肾病进展方面的效果。在进行5/6肾切除术后两周,将大鼠按体重、收缩压(SBP)和尿蛋白排泄率(UprotV)匹配分为五组。研究了分别用25和40 mg/L依那普利(I组和II组;每组n = 7)、180 mg/L氯沙坦(III组,n = 8)或依那普利(25 mg/L)+氯沙坦(180 mg/L)联合用药(IV组,n = 9)与赋形剂(V组,n = 9)治疗12周对SBP和UprotV的影响。然后对残余肾脏进行组织学评估,以寻找局灶节段性肾小球硬化和玻璃样变(FSGS)以及间质纤维化的证据。各组在任何时间的体重均无显著差异(NSD)。联合治疗在12周时使SBP显著降低(122±8 mmHg),降至与单独使用氯沙坦(127±3 mmHg)或依那普利(40 mg/L)(124±5 mmHg)相似的水平(与赋形剂对照组相比,P < 0.05)。在降压效果相当的情况下,各治疗组(II至IV组)之间FSGS的发生率没有差异(F = 1.7,NSD)。肾小管间质损伤评分也呈现类似模式。无论是在个体大鼠中(r = 0.68,P = 0.05)还是在各组均值之间(r = 0.99,P = 0.001),血压与FSGS的程度均高度相关。我们得出结论,在本研究的12周期间,依那普利、氯沙坦或联合治疗的肾脏保护作用相似,且与它们的降压作用强度密切相关。